Guggenheim raised the firm’s price target on Jade Biosciences (JBIO) to $23 from $17 and keeps a Buy rating on the shares ahead of “key” Phase 1 JADE101 data next quarter following the company’s Q4 report and business update late last week.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JBIO:
- Jade: Differentiated IgAN Profile and Multi-Asset Upside Make $2B Peak Sales for JADE101 Look Conservative
- Positioning Jade Biosciences as a Leading APRIL Inhibitor Play in IgA Nephropathy With Compelling Pipeline and Risk‑Reward
- Jade Biosciences price target raised to $40 from $19 at Stifel
- Jade Biosciences initiated with an Outperform at LifeSci Capital
- Jade Biosciences reports Q4 EPS ($3.19), consensus ($2.95)